Related Experiment Video
Updated: Dec 1, 2025
Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
Published on: February 9, 2024
Genomic landscape analyses in cervical carcinoma and consequences for treatment
Dominik Diefenbach1, Henry Johannes Greten2, Thomas Efferth1
1Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany.
Abstract:
Where we are on the road to 'tailor-made' precision medicine for drug-resistant cervical carcinoma? We explored studies about analyses of viral and human genomes, epigenomes and transcriptomes, DNA mutation analyses, their importance in detecting HPV sequences, mechanisms of drug resistance to established and targeted therapies with small molecule or therapeutic antibodies, to radiosensitivity and to chemoradiotherapy. The value of repurposing of old drugs initially approved for other disease indications and now considered for cervix cancer therapy is also discussed. The microbiome influences drug response and survival too. HPV genomic integration sites were less significant. Nomograms (Lee et al., 2013) even outperformed FIGO staging regarding prediction of five-year overall survival times. We conclude that there are still many loose threads to be followed up, before coherent conclusions for individualized therapy of drug-resistant cervical carcinoma can be drawn.
Insights
Precision medicine for drug-resistant cervical cancer requires further research into viral and human genomics, drug resistance mechanisms, and microbiome influences. Tailored therapies are not yet fully realized, despite promising avenues like drug repurposing.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Cervical carcinoma presents significant challenges, particularly drug-resistant forms.
- Developing "tailor-made" precision medicine is a critical unmet need.
Purpose of the Study:
- To review the current landscape of precision medicine approaches for drug-resistant cervical cancer.
- To identify key areas of research including genomic analyses, drug resistance mechanisms, and novel therapeutic strategies.
Main Methods:
- Comprehensive literature review of studies analyzing viral and human genomes, epigenomes, transcriptomes, and DNA mutations.
- Examination of mechanisms of resistance to conventional, targeted therapies, and chemoradiotherapy.
- Discussion of drug repurposing and the role of the microbiome in treatment response.
Main Results:
- Human papillomavirus (HPV) detection and genomic integration sites are important but require further investigation.
- Understanding drug resistance mechanisms is crucial for developing effective targeted therapies and antibodies.
- Drug repurposing and microbiome modulation show potential for improving treatment outcomes.
- Predictive models like nomograms may offer advantages over traditional staging systems.
Conclusions:
- Significant progress has been made, but many research areas require further exploration before individualized therapy for drug-resistant cervical cancer is achievable.
- Integrating genomic, epigenomic, transcriptomic, and microbiome data is essential for advancing precision oncology in cervical cancer.
